NCT05821179

Brief Summary

This study was designed to verify the role of salivary LINC00657 as a diagnostic marker in oral squamous cell carcinoma (OSCC) patients as compared to oral lichen planus (OLP) (as an example of oral potentially malignant lesions) and normal individuals, and to show its relation to miR-106a. A total of 36 participants were included.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 25, 2023

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

March 26, 2023

Completed
25 days until next milestone

First Posted

Study publicly available on registry

April 20, 2023

Completed
Last Updated

April 20, 2023

Status Verified

April 1, 2023

Enrollment Period

1 year

First QC Date

March 26, 2023

Last Update Submit

April 19, 2023

Conditions

Keywords

Oral squamous cell carcinoma, oral potentially malignant disorders, saliva, LINC00657, miR-106a.

Outcome Measures

Primary Outcomes (1)

  • LINC00657 level in salivary samples from all participants measured using PCR

    quantitative real-time PCR is used to detect LINC00657 levels in saliva samples from patients with OSCC and OPMD compared to healthy subjects

    level of miR-106a is measured after the completion of all salivary sample collection carried at the 1 day of enrollment of subjects in the investigation after diagnosis confirmation

Secondary Outcomes (1)

  • miR-106a level in salivary samples from the included subjects evaluated by PCR

    level of miR-106a is measured after the completion of all salivary sample collection carried at the 1 day of enrollment of subjects in the investigation

Study Arms (3)

Group I

12 patients diagnosed with OSCC.

Group II

12 patients diagnosed with OLP.

Group III

12 systemically free individuals with no oral mucosal lesions.

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

\- patients recruited from the outpatient clinic of departments of oral diagnosis and medicine and periodontology Fayoum, Beni-Suef and Ahram-Candian universities

You may qualify if:

  • group I : oral squamous cell carcinoma lesions (OSCC)
  • group II: oral lichen planus lesions (OLP)
  • group III: systemically healthy volunteers

You may not qualify if:

  • oral lesions other than OSCC / OLP in group I and II
  • any oral lesion in group III
  • pregnant females

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

faculty of dentistry, Fayoum university

Al Fayyum, Egypt

Location

Related Publications (1)

  • Tarrad NAF, Hassan S, Shaker OG, AbdelKawy M. "Salivary LINC00657 and miRNA-106a as diagnostic biomarkers for oral squamous cell carcinoma, an observational diagnostic study". BMC Oral Health. 2023 Dec 12;23(1):994. doi: 10.1186/s12903-023-03726-0.

Biospecimen

Retention: SAMPLES WITH DNA

saliva

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Condition Hierarchy (Ancestors)

Carcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsHead and Neck NeoplasmsNeoplasms by Site

Study Officials

  • Nayroz Tarrad, as. professor

    faculty of dentistry, Fayoum university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate professor

Study Record Dates

First Submitted

March 26, 2023

First Posted

April 20, 2023

Study Start

January 1, 2022

Primary Completion

January 1, 2023

Study Completion

February 25, 2023

Last Updated

April 20, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations